GlassScriptPhysician profile
Colby A Powell
NPI 1114988714
$1,490.48
in general payments reported to CMS, 2019-2025
21 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $625 · 2023: $332 · 2024: $155 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $291.58 | 2022-2023 | Xarelto |
| Abbvie INC. | $243.60 | 2021-2022 | |
| Inspire Medical Systems, INC. | $124.91 | 2023-2024 | Inspire |
| Eisai INC. | $122.85 | 2024 | |
| Emd Serono, INC. | $120.00 | 2025 | Mavenclad |
| Argenx US, INC. | $114.11 | 2023 | Vyvgart |
| Biohaven Pharmaceuticals, INC. | $104.73 | 2021 | |
| Amgen INC. | $52.16 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.90 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.60 | 2022 | |
| Lilly USA, LLC | $34.99 | 2022 | |
| Neurelis, INC. | $31.42 | 2022-2023 | Valtoco |
| Genzyme Corporation | $25.37 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $18.58 | 2022 | |
| Lundbeck LLC | $17.52 | 2023 | Vyepti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $17.43 | 2021 | |
| Merz Pharmaceuticals, LLC | $16.85 | 2023 | Xeomin |
| Sk Life Science, INC. | $16.32 | 2022 | |
| Impel Pharmaceuticals INC. | $15.40 | 2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $14.32 | 2023 | Koselugo |
| Amneal Pharmaceuticals LLC | $13.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colby Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.